Our study indicates that inactivation of GNA13 alone could lead to higher expression of BCL2 that eventually conferred higher drug sensitivity to BCL2 inhibitor, implying that DLBCL patients with inactive mutations of GNA13 are more sensitive to the BCL2 inhibitor treatment, providing a patient-stratification biomarker for the venetoclax therapy. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.